Microdox may be available in the countries listed below.
Doxycycline hydrochloride (a derivative of Doxycycline) is reported as an ingredient of Microdox in the following countries:
International Drug Name Search
Gynosant may be available in the countries listed below.
Fluconazole is reported as an ingredient of Gynosant in the following countries:
International Drug Name Search
Loprolol may be available in the countries listed below.
Metoprolol tartrate (a derivative of Metoprolol) is reported as an ingredient of Loprolol in the following countries:
International Drug Name Search
The following drugs and medications are in some way related to, or used in the treatment of Premenstrual Dysphoric Disorder. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Medical Encyclopedia:
Atropinesulfaat ratiopharm may be available in the countries listed below.
Atropine sulfate (a derivative of Atropine) is reported as an ingredient of Atropinesulfaat ratiopharm in the following countries:
International Drug Name Search
Sedusen may be available in the countries listed below.
Sulpiride is reported as an ingredient of Sedusen in the following countries:
International Drug Name Search
Generic Name: fludarabine (oral) (floo DAR a been)
Brand Names: Oforta
Fludarabine is a cancer medication that interferes with the growth and spread of cancer cells in the body.
Fludarabine is used to treat B-cell chronic lymphocytic leukemia (CLL).
Fludarabine is usually given after other cancer medications have been tried without successful response to treatment.
Fludarabine may also be used for other purposes not listed in this medication guide.
Before you take fludarabine, tell your doctor if you have kidney disease, bone marrow problems, or a weak immune system.
Fludarabine can lower blood cells that help your body fight infections. This can make it easier for you to bleed from an injury or get sick from being around others who are ill. Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection. Your blood may need to be tested often. Visit your doctor regularly.
Contact your doctor at once if you develop signs of infection such as fever, cough, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, mouth sores, or unusual weakness.
If you have any of these other conditions, you may need a fludarabine dose adjustment or special tests:
bone marrow problems; or
a weak immune system.
Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.
Fludarabine is usually taken daily for 5 days in a row every 28 days. Once your body has responded well to the medication, your doctor may recommend additional treatment cycles.
Fludarabine may be taken with or without food.
If you accidentally touch a broken tablet, wash your skin with soap and water. Call your doctor if you develop a skin rash or severe irritation.
Fludarabine can lower blood cells that help your body fight infections. This can make it easier for you to bleed from an injury or get sick from being around others who are ill.
Contact your doctor at once if you develop signs of infection such as fever, cough, sore throat, flu symptoms, easy bruising or bleeding (nosebleeds, bleeding gums), loss of appetite, nausea and vomiting, mouth sores, or unusual weakness.
Your blood will need to be tested often. Your cancer treatments may be delayed based on the results of these tests. Visit your doctor regularly.
Keep each tablet in its blister pack until you are ready to take it. Push a tablet through the foil when you are ready to take the medicine.
Do not throw away unused or expired fludarabine tablets in your household trash. Ask your pharmacist where to locate a community pharmaceutical take back disposal program.
See also: Oforta dosage (in more detail)
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include fever, chills, flu symptoms, mouth sores, easy bruising or bleeding, purple or red spots under your skin, behavior changes, and vision loss.
Avoid activities that increase your risk of bleeding or injury. Brush your teeth gently and use extra care while shaving.
pale or yellowed skin, dark colored urine;
fast or slow heart rate, weak pulse, trouble concentrating, feeling tired or short of breath;
easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
fever, chills, body aches, flu symptoms, sores in your mouth and throat, nausea, vomiting, loss of appetite;
vision problems, confusion, agitation, changes in behavior, or feeling like you might pass out;
cough with yellow or green mucus, stabbing chest pain, trouble breathing;
black or bloody stools, coughing up blood;
lower back pain, blood in your urine, pain or burning when you urinate;
urinating less than usual or not at all;
numbness or tingly feeling around your mouth; or
muscle weakness, tightness, or contraction, overactive reflexes.
Less serious side effects may include:
muscle pain;
swelling in your legs;
mild nausea, diarrhea, stomach pain;
cold symptoms such as runny or stuffy nose, sneezing;
sweating; or
mild itching or skin rash.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
There may be other drugs that can interact with fludarabine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.
See also: Oforta side effects (in more detail)
Binaldan may be available in the countries listed below.
Loperamide hydrochloride (a derivative of Loperamide) is reported as an ingredient of Binaldan in the following countries:
International Drug Name Search
Virexen may be available in the countries listed below.
Idoxuridine is reported as an ingredient of Virexen in the following countries:
International Drug Name Search
Valaplex may be available in the countries listed below.
Valsartan is reported as an ingredient of Valaplex in the following countries:
International Drug Name Search
Marinzoal may be available in the countries listed below.
Bifonazole is reported as an ingredient of Marinzoal in the following countries:
International Drug Name Search
Triflusal Alter may be available in the countries listed below.
Triflusal is reported as an ingredient of Triflusal Alter in the following countries:
International Drug Name Search
Heparin ukonserveret SAD may be available in the countries listed below.
Heparin sodium salt (a derivative of Heparin) is reported as an ingredient of Heparin ukonserveret SAD in the following countries:
International Drug Name Search
Dalacin C Phosphate may be available in the countries listed below.
Clindamycin dihydrogen phosphate (a derivative of Clindamycin) is reported as an ingredient of Dalacin C Phosphate in the following countries:
International Drug Name Search
Enalapril Tecnigen may be available in the countries listed below.
Enalapril maleate (a derivative of Enalapril) is reported as an ingredient of Enalapril Tecnigen in the following countries:
International Drug Name Search
Generic Name: methamphetamine (METH am FET a meen)
Brand Names: Desoxyn
Methamphetamine is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control.
Methamphetamine is used to treat attention deficit hyperactivity disorder (ADHD). It is also used to treat obesity after other diets or medications have been tried without successful weight loss.
Methamphetamine may also be used for other purposes not listed in this medication guide.
Long-term use of methamphetamine can slow a child's growth. Tell your doctor if the child using this medication is not growing or gaining weight properly.
Do not use this medication if you are allergic to methamphetamine or if you have:
heart disease or moderate to severe high blood pressure (hypertension);
arteriosclerosis (hardening of the arteries);
overactive thyroid;
glaucoma;
severe anxiety, tension, or agitation; or
if you have a history of drug or alcohol addiction.
If you have any of these conditions, you may need a dose adjustment or special tests to safely use this medication:
a congenital heart defect;
high blood pressure;
heart failure, heart rhythm disorder, or recent heart attack;
a personal or family history of mental illness, psychotic disorder, bipolar illness, depression, or suicide attempt;
diabetes; or
tics (muscle twitches) or Tourette's syndrome.
Long-term use of methamphetamine can slow a child's growth. Tell your doctor if the child using this medication is not growing or gaining weight properly.
Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label.
Your doctor may occasionally change your dose to make sure you get the best results from this medication.
If you are taking methamphetamine for weight loss and your appetite gradually increases, do not take more of the medication to suppress appetite. Stop taking methamphetamine and call your doctor.
To be sure this medication is helping your condition, your doctor will need to see you on a regular basis. Do not miss any scheduled visits.
This medication can cause you to have unusual results with certain medical tests. Tell any doctor who treats you that you are using methamphetamine.
See also: Desoxyn dosage (in more detail)
Take the missed dose as soon as you remember. If it is almost time for your next dose, or if it is already evening, skip the missed dose and take the medicine the next morning. Taking this medicine late in the day can cause sleep problems. Do not take extra medicine to make up the missed dose.
Overdose symptoms may include restlessness, tremor, muscle twitches, rapid breathing, confusion, hallucinations, panic, aggressiveness, unexplained muscle pain or tenderness, muscle weakness, fever or flu symptoms, and dark colored urine. These symptoms may be followed by depression and tiredness. Other overdose symptoms include nausea, vomiting, diarrhea, stomach pain, uneven heartbeats, feeling light-headed, fainting, seizure (convulsions), or coma.
Do not take methamphetamine late in the day. A dose taken too late in the day can cause sleep problems (insomnia).
Avoid drinking fruit juices or taking vitamin C at the same time you take methamphetamine. These can make your body absorb less of the medicine.
fast, pounding, or uneven heartbeats;
feeling light-headed, fainting;
dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure); or
tremor, restlessness, hallucinations, unusual behavior, or motor tics (muscle twitches).
Less serious side effects may include:
headache or dizziness;
sleep problems (insomnia);
dry mouth or an unpleasant taste in your mouth;
diarrhea, constipation;
loss of appetite, weight loss; or
loss of interest in sex, impotence, or difficulty having an orgasm.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Tell your doctor about all other medications you use, especially:
insulin;
cold medicines (decongestants);
phenothiazines such as chlorpromazine (Thorazine), prochlorperazine (Compazine, Compro), promethazine (Pentazine, Phenergan, Anergan, Antinaus), thioridazine (Mellaril), and others;
an antidepressant such as amitriptyline (Elavil), amoxapine (Asendin), clomipramine (Anafranil), desipramine (Norpramin), imipramine (Tofranil), or nortriptyline (Pamelor).
This list is not complete and there may be other drugs that can interact with methamphetamine. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.
See also: Desoxyn side effects (in more detail)
Ciprofloxacin Lactate may be available in the countries listed below.
Ciprofloxacin Lactate (BANM) is known as Ciprofloxacin in the US.
International Drug Name Search
Glossary
| BANM | British Approved Name (Modified) |
Betametasona Sodio Fosfato may be available in the countries listed below.
Betamethasone 21-(disodium phosphate) (a derivative of Betamethasone) is reported as an ingredient of Betametasona Sodio Fosfato in the following countries:
International Drug Name Search
Melicam may be available in the countries listed below.
Meloxicam is reported as an ingredient of Melicam in the following countries:
International Drug Name Search
Acetylcysteine Sandoz Conseil may be available in the countries listed below.
Acetylcysteine is reported as an ingredient of Acetylcysteine Sandoz Conseil in the following countries:
International Drug Name Search
Espimax may be available in the countries listed below.
Spironolactone is reported as an ingredient of Espimax in the following countries:
International Drug Name Search
Captopress may be available in the countries listed below.
Captopril is reported as an ingredient of Captopress in the following countries:
International Drug Name Search
Calcium (pantothénate de) may be available in the countries listed below.
Calcium (pantothénate de) (DCF) is also known as Calcium Pantothenate (Rec.INN)
International Drug Name Search
Glossary
| DCF | Dénomination Commune Française |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Cardigard may be available in the countries listed below.
Carvedilol is reported as an ingredient of Cardigard in the following countries:
International Drug Name Search
Mecisteina may be available in the countries listed below.
Mecisteina (DCIT) is also known as Mecysteine (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Tenotryl may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Enrofloxacin is reported as an ingredient of Tenotryl in the following countries:
International Drug Name Search
Methionin AL may be available in the countries listed below.
Methionine is reported as an ingredient of Methionin AL in the following countries:
International Drug Name Search
Digifungin may be available in the countries listed below.
Tolnaftate is reported as an ingredient of Digifungin in the following countries:
International Drug Name Search
Pharmasin may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Tylosin is reported as an ingredient of Pharmasin in the following countries:
International Drug Name Search
Claritromicina MK may be available in the countries listed below.
Clarithromycin is reported as an ingredient of Claritromicina MK in the following countries:
International Drug Name Search
Tenex is a brand name of guanfacine, approved by the FDA in the following formulation(s):
Yes. The following products are equivalent to Tenex:
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tenex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Tenex.
Bayslowth may be available in the countries listed below.
Voglibose is reported as an ingredient of Bayslowth in the following countries:
International Drug Name Search
GO-ON may be available in the countries listed below.
Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of GO-ON in the following countries:
International Drug Name Search
Glimepirida Calox may be available in the countries listed below.
Glimepiride is reported as an ingredient of Glimepirida Calox in the following countries:
International Drug Name Search
5% Dextrose Injection, USP in the MINI-BAG Plus Container is a sterile, nonpyrogenic solution for intravenous administration after admixture with a single dose powdered drug. It contains no antimicrobial agents. Each 100 mL contains 5 g of Dextrose Hydrous, USP. The osmolarity is 252 m0smol/L (calculated). The pH is 4.0 (3.2 to 6.5). The chemical structure for Dextrose Hydrous, USP is shown below.
The MINI-BAG Plus Container is a standard diluent container with an integral drug vial adaptor. It allows for drug admixture after connection to a single dose powdered drug vial having a 20 mm closure. A breakaway seal in the tube between the vial adaptor and the container is broken to allow transfer of the diluent into the vial and reconstitution of the drug. The reconstituted drug is then transferred from the vial into the container diluent and mixed to result in an admixture for delivery to the patient.
The VIAFLEX plastic container is fabricated from polyvinyl chloride (PL 146 Plastic). Exposure to temperatures above 25° C/77° F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container can leach out certain of its chemical components in very small amounts within the expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts per million. However, the safety of the plastic has been confirmed in tests in animals according to USP biological tests for plastic containers as well as by tissue culture toxicity studies.
5% Dextrose Injection, USP has value as a source of water and calories. It has a caloric content of approximately 170 kcal/L. It is capable of inducing diuresis depending on the clinical condition of the patient.
5% Dextrose Injection, USP is indicated as a source of water and calories and may also be used as diluent for reconstitution of a powdered drug product packaged in a vial with a 20 mm closure.
Solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.
Dextrose injections should not be administered simultaneously with blood through the same administration set because of the possibility of pseudoagglutination or hemolysis.
The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutive states is inversely proportional to the electrolyte concentrations of the injections. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injections.
Excessive administration of dextrose injections may result in significant hypokalemia.
For use only with a single dose powdered drug vial with a 20 mm closure.
Do not administer unless drug is completely dissolved and drug vial is empty.
Additives may be incompatible.
Do not remove drug vial at any time prior to or during administration.
In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible intracerebral hemorrhage.
Do not administer unless solution is clear and all seals are intact. Dextrose injections should be used with caution in patients with overt or subclinical diabetes mellitus.
Clinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations, and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation.
Studies with 5% Dextrose Injection, USP have not been performed to evaluate the carcinogenic potential, mutagenic potential or effects on fertility.
Animal reproduction studies have not been conducted with 5% Dextrose Injection, USP. It is also not known whether Dextrose Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Dextrose Injection, USP should be given to a pregnant woman only if clearly needed.
Caution should be exercised when 5% Dextrose Injection, USP is administered to a nursing woman.
Dextrose is safe and effective for the stated indications in pediatric patients (see INDICATIONS AND USAGE ). As reported in the literature, the dosage selection and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low birth weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Frequent monitoring of serum glucose concentrations is required when dextrose is prescribed to pediatric patients, particularly neonates and low birth weight infants.
Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.
If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures and save the remainder of the fluid for examination if deemed necessary.
As directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
All injections in MINI-BAG Plus Containers are intended for intravenous administration using sterile equipment.
Do not remove unit from overwrap until ready for use. The overwrap is a moisture barrier.
Tear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity should diminish gradually.
Prior to use, check that the vial adaptor cover is intact. Check the solution container for minute leaks by squeezing inner bag firmly. If leaks are found or if the vial adaptor cover is not intact, discard product as sterility may be impaired.
See other side for detailed instructions.
Additives may be incompatible.
5% Dextrose Injection, USP in MINI-BAG Plus Container is available as follows:
| Code | Size (mL) | NDC |
| 2B0040 | 50 mL | NDC 0338-0551-11 |
| 2B0041 | 100 mL | NDC 0338-0551-18 |
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C/77° F).
7. Remove port protector. Attach administration set per its directions.
8. Hang container on I.V. pole and prime set per directions. Ensure that vial is empty of drug and solution. Repeat step 6 if drug and solution remain in vial.
Warning: Do not use in series connections.
9. Administer medication per directions. Use within specified time for drug stability. Refer to drug package insert.
Baxter Healthcare Corporation
Deerfield, IL 60015 USA
Printed in USA
BAXTER, VIAFLEX, MINI-BAG, and PL-146 are trademarks of Baxter International Inc.
©Copyright 1990, 1991, 1992, 1995, Baxter Healthcare Corporation. All rights reserved.
07-19-38-682 Rev. June, 2003
5% Dextrose Injection, USP Container Label
LOT EXP
5% Dextrose
Injection USP
MINI-BAG Plus Container
50mL
2B0040
NDC 0338-0551-11
EACH 50 mL CONTAINS 2.5 g DEXTROSE HYDROUS USP
pH 4.0 (3.2 TO 6.5) OSMOLARITY 252 mOsmol/L
(CALC) STERILE NONPYROGENIC READ PACKAGE INSERT FOR FULL
INFORMATION ADDITIVES MAY BE INCOMPATIBLE DOSAGE
INTRAVENOUSLY AS DIRECTED BY A PHYSICIAN CAUTIONS MUST NOT BE
USED IN SERIES CONNECTIONS DO NOT ADMINISTER SIMULTANEOUSLY
WITH BLOOD DO NOT USE UNLESS SOLUTION IS CLEAR RX ONLY
US PAT NOS 4 340 049 4 607 671 5 304 163
BAXTER HEALTHCARE CORPORATION
DEERFIELD IL 60015 USA
MADE IN USA
VIAFLEX SINGLE DOSE CONTAINER
PL 146 PLASTIC
BAXTER VIAFLEX MINI-BAG
AND PL 146 ARE TRADEMARKS OF
BAXTER INTERNATIONAL INC
BREAK SEAL AND MIX BEFORE USE
5% Dextrose Injection, USP Carton Label
Lot:PXX Exp:XX XX
QTY:80-50mL
Code: 2B0040
NDC: 0338-0551-11
5% DEXTROSE INJECTION, USP
IN MINI-BAG PLUS CONTAINER
(17) XXXX00 (10) PXX
(01) 50303380551113
| DEXTROSE dextrose injection | ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| ANDA | ANDA020179 | 12/07/1992 | |
| Labeler - BAXTER HEALTHCARE CORPORATION (005083209) |
| Establishment | |||
| Name | Address | ID/FEI | Operations |
| BAXTER HEALTHCARE SA, dba Baxter Healthcare of Puerto Rico | 189326168 | MANUFACTURE | |
Egozite Cradle Cap Lotion may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Egozite Cradle Cap Lotion in the following countries:
Salicylic Acid is reported as an ingredient of Egozite Cradle Cap Lotion in the following countries:
International Drug Name Search
Andol may be available in the countries listed below.
Acetylsalicylic Acid is reported as an ingredient of Andol in the following countries:
Ascorbic Acid is reported as an ingredient of Andol in the following countries:
International Drug Name Search
Cardiagen HCT may be available in the countries listed below.
Captopril is reported as an ingredient of Cardiagen HCT in the following countries:
Hydrochlorothiazide is reported as an ingredient of Cardiagen HCT in the following countries:
International Drug Name Search
Paracetamol / Ascorbinezuur may be available in the countries listed below.
Ascorbic Acid is reported as an ingredient of Paracetamol / Ascorbinezuur in the following countries:
Paracetamol is reported as an ingredient of Paracetamol / Ascorbinezuur in the following countries:
International Drug Name Search
The following drugs and medications are in some way related to, or used in the treatment of Crohn's Disease. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
See sub-topics
Medical Encyclopedia:
Harvard Health Guide:
Dexalocal may be available in the countries listed below.
Budesonide is reported as an ingredient of Dexalocal in the following countries:
Dexamethasone is reported as an ingredient of Dexalocal in the following countries:
Framycetin sulfate (a derivative of Framycetin) is reported as an ingredient of Dexalocal in the following countries:
International Drug Name Search
Omar may be available in the countries listed below.
Omeprazole is reported as an ingredient of Omar in the following countries:
International Drug Name Search
Reotal may be available in the countries listed below.
Pentoxifylline is reported as an ingredient of Reotal in the following countries:
International Drug Name Search
Verpirol may be available in the countries listed below.
Piperazine is reported as an ingredient of Verpirol in the following countries:
International Drug Name Search
Setard may be available in the countries listed below.
Cimetidine is reported as an ingredient of Setard in the following countries:
International Drug Name Search
Trédémine may be available in the countries listed below.
Niclosamide is reported as an ingredient of Trédémine in the following countries:
International Drug Name Search
Sodium Bicarbonate is reported as an ingredient of Soda Mint in the following countries:
International Drug Name Search
Chlorcol may be available in the countries listed below.
Chloramphenicol is reported as an ingredient of Chlorcol in the following countries:
International Drug Name Search
Co-Dopa may be available in the countries listed below.
Carbidopa is reported as an ingredient of Co-Dopa in the following countries:
Levodopa is reported as an ingredient of Co-Dopa in the following countries:
International Drug Name Search
Takepron may be available in the countries listed below.
Lansoprazole is reported as an ingredient of Takepron in the following countries:
International Drug Name Search
Hoof may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Biotin is reported as an ingredient of Hoof in the following countries:
International Drug Name Search
Sonigen may be available in the countries listed below.
Betamethasone 17α-valerate (a derivative of Betamethasone) is reported as an ingredient of Sonigen in the following countries:
Gentamicin sulfate (a derivative of Gentamicin) is reported as an ingredient of Sonigen in the following countries:
International Drug Name Search
Cefa-Tabs may be available in the countries listed below.
In some countries, this medicine may only be approved for veterinary use.
Cefadroxil is reported as an ingredient of Cefa-Tabs in the following countries:
International Drug Name Search
Spasmorelax may be available in the countries listed below.
Tetrazepam is reported as an ingredient of Spasmorelax in the following countries:
International Drug Name Search
Salicylic Acid is reported as an ingredient of Propa pH in the following countries:
International Drug Name Search
Novarin may be available in the countries listed below.
Diclofenac diethylamine (a derivative of Diclofenac) is reported as an ingredient of Novarin in the following countries:
Diclofenac sodium salt (a derivative of Diclofenac) is reported as an ingredient of Novarin in the following countries:
International Drug Name Search
Lexin may be available in the countries listed below.
Carbamazepine is reported as an ingredient of Lexin in the following countries:
Cefalexin is reported as an ingredient of Lexin in the following countries:
Cefalexin monohydrate (a derivative of Cefalexin) is reported as an ingredient of Lexin in the following countries:
International Drug Name Search
Ceproblock may be available in the countries listed below.
Celiprolol hydrochloride (a derivative of Celiprolol) is reported as an ingredient of Ceproblock in the following countries:
International Drug Name Search
Lansoprazol Hexal may be available in the countries listed below.
Lansoprazole is reported as an ingredient of Lansoprazol Hexal in the following countries:
International Drug Name Search
Nicarun may be available in the countries listed below.
Nicardipine hydrochloride (a derivative of Nicardipine) is reported as an ingredient of Nicarun in the following countries:
International Drug Name Search
Sebosel may be available in the countries listed below.
Selenium Sulfide is reported as an ingredient of Sebosel in the following countries:
International Drug Name Search
Generic Name: zidovudine (Intravenous route)
zye-DOE-vue-deen
Zidovudine has been associated with hematologic toxicity, including neutropenia and severe anemia, particularly in patients with advanced HIV disease. Prolonged use of zidovudine has been associated with symptomatic myopathy. Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported .
In the U.S.
Available Dosage Forms:
Therapeutic Class: Antiretroviral Agent
Pharmacologic Class: Nucleoside Reverse Transcriptase Inhibitor
Zidovudine (also known as AZT) injection is used in combination with other anti-virus medicines in the treatment of the infection caused by the human immunodeficiency virus (HIV). HIV is the virus responsible for acquired immune deficiency syndrome (AIDS). Zidovudine injection is used to slow the progression of disease in patients infected with HIV who have advanced symptoms, early symptoms, or no symptoms at all. This medicine also is used to help prevent pregnant women who have HIV from passing the virus to their babies during pregnancy and at birth.
Zidovudine injection will not cure or prevent HIV infection or AIDS; however, it helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay the development of problems usually related to AIDS or HIV disease. Zidovudine injection will not keep you from spreading HIV to other people. People who receive this medicine may continue to have the problems usually related to AIDS or HIV disease.
This medicine is available only with your doctor's prescription.
In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:
Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.
Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of zidovudine injection in children.
Although appropriate studies on the relationship of age to the effects of zidovudine injection have not been performed in the geriatric population, no geriatric-specific problems have been documented to date. However, elderly patients are more likely to have age-related liver, kidney, or heart problems which may require caution and an adjustment of dosage in patients receiving zidovudine injection.
| Pregnancy Category | Explanation | |
|---|---|---|
| All Trimesters | C | Animal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women. |
There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.
Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.
The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:
A nurse or other trained health professional will give you this medicine. This medicine is given through a needle placed in one of your veins.
Your doctor may give you a few doses of this medicine until your condition improves, and then you may be switched to an oral medicine that works the same way. If you have any concerns about this, talk to your doctor.
It is very important that your doctor check you or your child's progress at regular visits to make sure that this medicine is working properly. Blood tests may be needed to check for unwanted effects.
Do not receive this medicine if you are also using any combination medicines that also contain zidovudine (e.g., Combivir® or Trizivir®). To do so may increase the amount of zidovudine in your body which may cause serious side effects. Also, do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.
Zidovudine injection may cause blood problems. These problems may result in a greater chance of certain infections and slow healing. Therefore, you or your child should be careful when using regular toothbrushes, dental floss, and toothpicks not to damage your gums. Check with your medical doctor or dentist if you have any questions about proper oral hygiene (mouth care) during treatment.
Check with your doctor if you have muscle pain, tenderness, wasting, or unusual tiredness or weakness while you are receiving this medicine.
Two rare but serious reactions to this medicine are lactic acidosis (too much acid in the blood) and liver toxicity, which includes an enlarged liver. These are more common if you are female, very overweight (obese), or have been taking anti-HIV medicines for a long time. Call your doctor right away if you or your child have more than one of these symptoms: abdominal discomfort or cramping; dark urine; decreased appetite; diarrhea; general feeling of discomfort; light-colored stools; muscle cramping or pain; nausea; unusual tiredness or weakness; trouble breathing; vomiting; or yellow eyes or skin.
When you or your child start taking HIV medicines, your immune system may get stronger. If you have infections that are hidden in your body (e.g., pneumonia or tuberculosis), you may notice new symptoms when your body tries to fight them. If this occurs, tell your doctor right away.
You should not breastfeed if you have HIV or AIDS, because you may give the infection to your baby through your breast milk.
Zidovudine injection does not decrease the risk of transmitting the HIV infection to others through sexual contact or by contamination through blood. HIV may be spread to others through infected body fluids, including blood, vaginal fluid, or semen. If you are infected, it is best to avoid any sexual activity involving an exchange of body fluids with other people. If you do have sex, always wear (or have your partner wear) a condom (“rubber”). Only use condoms made of latex or polyurethane and use them every time you have contact with semen, vaginal secretions, or blood. Also, do not share needles with anyone or use dirty needles. If you have any questions about this, check with your doctor.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur:
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
See also: Retrovir Intravenous side effects (in more detail)
The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.
The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.
